Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis

被引：0
|
作者：
Evan W. Davies
Louis S. Matza
Gavin Worth
David H. Feeny
Jacqueline Kostelec
Steven Soroka
David Mendelssohn
Philip McFarlane
Vasily Belozeroff
机构：
[1] Outcomes Research,Department of Economics
[2] Evidera,Department of Medicine
[3] Outcomes Research,Department of Nephrology
[4] Evidera,Division of Nephrology
[5] Amgen (Europe) GmbH,undefined
[6] McMaster University,undefined
[7] Dalhousie University,undefined
[8] Humber River Hospital,undefined
[9] St. Michael’s Hospital,undefined
[10] Amgen,undefined
[11] Inc,undefined
来源：
Health and Quality of Life Outcomes | / 13卷
关键词：
Utility; Chronic kidney disease; Secondary hyperparathyroidism; End-stage renal disease; Standard gamble;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
    Davies, Evan W.
    Matza, Louis S.
    Worth, Gavin
    Feeny, David H.
    Kostelec, Jacqueline
    Soroka, Steven
    Mendelssohn, David
    McFarlane, Philip
    Belozeroff, Vasily
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
  • [2] IMPACT OF MAJOR CLINICAL EVENTS ON UTILITIES IN THE CONTEXT OF SECONDARY HYPERPARATHYROIDISM (SHPT) AND CHRONIC KIDNEY DISEASE CKD) TREATED WITH DIALYSIS
    Davies, E. W.
    Matza, L. S.
    Worth, G.
    Feeny, D. H.
    Kostelec, J.
    Soroka, S. D.
    Mendelssohn, D. C.
    McFarlane, P. A.
    Belozeroff, V
    VALUE IN HEALTH, 2013, 16 (07) : A634 - A634
  • [3] Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease
    Costa, Tiago Emanuel M.
    Lauar, Julia C.
    Innecchi, Mariana L. R.
    Coelho, Venceslau A.
    Moyses, Rosa M. A.
    Elias, Rosilene M.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (09) : 2255 - 2261
  • [4] Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease
    Tiago Emanuel M. Costa
    Julia C. Lauar
    Mariana L. R. Innecchi
    Venceslau A. Coelho
    Rosa M. A. Moysés
    Rosilene M. Elias
    International Urology and Nephrology, 2022, 54 : 2255 - 2261
  • [5] Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
    Perez-Ricart, Ariadna
    Galicia-Basart, Maria
    Alcalde-Rodrigo, Maria
    Segarra-Medrano, Alfons
    Sune-Negre, Josep-Maria
    Montoro-Ronsano, Jose-Bruno
    PLOS ONE, 2016, 11 (09):
  • [6] Management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis in Togo
    Dosseh, E. D.
    Kassegne, I
    Sakiye, K.
    Adambounou, A.
    Yawovi, James E.
    Djagadou, K.
    Kossidje, K.
    Ayite, A. E.
    MEDECINE ET SANTE TROPICALES, 2012, 22 (01): : 65 - 68
  • [7] High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina
    Douthat, Walter G.
    Castellano, Mauro
    Berenguer, Leandro
    Alejandra Guzman, M.
    de Arteaga, Javier
    Chiurchiu, Carlos R.
    Massari, Pablo U.
    Garay, Gabriela
    Capra, Raul
    de la Fuente, Jorge L.
    NEFROLOGIA, 2013, 33 (05): : 657 - 666
  • [8] Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
    Xu, Yang
    Evans, Marie
    Soro, Marco
    Barany, Peter
    Carrero, Juan Jesus
    CLINICAL KIDNEY JOURNAL, 2021, 14 (10) : 2213 - 2220
  • [9] Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease
    Wei, Yudan
    Lin, Jing
    Yang, Fan
    Li, Xiujiang
    Hou, Yue
    Lu, Ronghua
    Shi, Xiaonv
    Liu, Zhi
    Du, Yujun
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 12 (02) : 1206 - 1212
  • [10] Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
    Abbas, Fizza
    Coyne, Daniel W.
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2019, 38 (02) : 141 - 144
12345